INCY241220C77500
- 1.98
- 0.000.00%
Incyte Newsroom
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $86
TD Cowen Remains a Buy on Incyte (INCY)
TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating
Incyte Is Maintained at Sector Perform by RBC Capital
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86
Incyte Analyst Ratings
Stifel Nicolaus Sticks to Its Hold Rating for Incyte (INCY)
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $52 to $86
TD Cowen Remains a Buy on Incyte (INCY)
Incyte Faces Pipeline Setbacks and Growth Challenges, Justifying Sell Rating
Incyte's Strategic Growth Potential and Rich Pipeline Underpin Buy Rating at $86 Target
RBC Cuts Price Target on Incyte to $74 From $80, Keeps Sector Perform Rating
Incyte's Trials and Challenges: Hold Recommendation Amid Clinical and Financial Uncertainties
Incyte Is Maintained at Sector Perform by RBC Capital
Incyte Analyst Ratings
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $80 to $97
Goldman Sachs Maintains Neutral on Incyte, Raises Price Target to $70
Incyte Is Maintained at Neutral by JP Morgan